Terminology Service < Semantic Lookup Platform

All terms in NCIT

Label	Id	Description
Flavone Acetic Acid/Interleukin-2	NCIT_C15520
Agent Combination Not Indexed in Open Clinical Trials	NCIT_C61063
Recombinant Interleukin-2	NCIT_C587	[Any recombinant analog of endogenous interleukin-2 (IL-2), a cytokine involved in intercellular communication related to cell differentiation, proliferation, inflammation, hematopoiesis, neuronal functions, and release of hormones. IL-2 binds to and activates specific receptors, triggering expression of specific genes, and may induce T cell-mediated tumor regression in some tumor types.]
Mitoflaxone	NCIT_C1101	[A synthetic flavonoid with vascular targeting properties. Flavone acetic acid exhibits an antiproliferative effect on endothelial cells as a result of a superoxide-dependent mechanism, which induces changes in permeability of the vasculature of the tumor. This agent may stimulate tumor necrosis and promote shunting of blood flow to viable regions of the tumor, increasing their oxygenation and rendering them more susceptible to the antitumor effects of hyperthermia and ionizing radiation. (NCI04)]
Antiprogesterone Therapy	NCIT_C15521	[Drug treatment to block the action of the female hormone progesterone.]
Antihormone Therapy	NCIT_C94632
Interleukin-2/Tumor Necrosis Factor	NCIT_C15522
Recombinant Tumor Necrosis Factor-Alpha	NCIT_C913	[A recombinant therapeutic agent which is chemically identical to or similar to the endogenous cytokine tumor necrosis factor-alpha with antineoplastic properties. Tumor necrosis factor-alpha binds to and activates "death receptors" on the cell surface, resulting in apoptosis and cell death by the p53-independent extrinsic pathway. This agent also disrupts tumor vascularization. (NCI04)]
Interleukin-2/Tumor Infiltrating Lymphocytes	NCIT_C15523
Therapeutic Tumor Infiltrating Lymphocytes	NCIT_C28699	[A preparation of cells, consisting of autologous tumor infiltrating lymphocytes, that are manipulated in vitro and, upon administration in vivo, re-infiltrate the tumor to initiate tumor cell lysis. In vitro, therapeutic tumor-infiltrating lymphocytes (TILs) are isolated from tumor tissue and cultured with lymphokines such as interleukin-2; the therapeutic TILs are then infused into the patient, where, after re-infiltration of the tumor, they may induce lysis of tumor cells and tumor regression. The use of therapeutic TILs is considered a form of adoptive immunotherapy.]
Tumor Infiltrating Lymphocyte Therapy	NCIT_C15524	[A form of adoptive cell transfer in which lymphocytes are isolated from a patient's tumor, grown in vitro, and then infused into the patient in combination with interleukin 2.]
Leukocyte Therapy	NCIT_C15545
Aromatase Inhibition Therapy	NCIT_C15525	[Drug treatment to block the action of aromatases, thereby reducing estrogen biosynthesis.]
Antiestrogen Therapy	NCIT_C15757	[Drug treatment to block the action of the female hormone estrogen.]
5a-Reductase Inhibition	NCIT_C15526	[Treatment with a 5a-reductase inhibitor with the goal of suppressing the conversion of testosterone to dihydrotestosterone.]
Antiandrogen Therapy	NCIT_C15481	[A therapeutic regimen that utilizes pharmaceuticals to reduce serum levels of male sex hormones.]
Interleukin-2/Sargramostim	NCIT_C15527
Sargramostim	NCIT_C1492	[A recombinant therapeutic agent chemically identical to endogenous human GM-CSF except a leucine substitution in position 23. Binding to specific cell surface receptors, sargramostim modulates the proliferation and differentiation of a variety of hematopoietic progenitor cells with some specificity towards stimulation of leukocyte production and may reverse treatment-induced neutropenias. This agent also promotes antigen presentation, up-regulates antibody-dependent cellular cytotoxicity (ADCC), and increases interleukin-2-mediated lymphokine-activated killer cell function; it may also augment host antitumoral immunity.]
Interleukin-2/Monoclonal Antibody Lym-1	NCIT_C15528
Monoclonal Antibody Lym-1	NCIT_C1561	[A murine IgG2a monoclonal antibody directed against the HLA-Dr10 protein, a cell surface marker present on over eighty percent of lymphoma cells. When conjugated with a radioactive isotope, Lym-1 monoclonal antibody selectively transports the cytotoxic radioisotope to HLA-Dr10-expressing tumor cells, thereby sparing healthy B-cells and normal tissues. This agent also mediates antibody-dependent cytotoxicity thereby promoting Raji B-lymphoid cell lysis by human neutrophils. (NCI04)]